Medtech Execs On The Move, September 2015
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
You may also be interested in...
Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.
From the latest COVID-19 advances to the emergence of game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
The Belgian group is the latest to be hit by the FDA's difficulties in address the growing backlog of facility inspections, leaving bimekizumab in limbo in the US, despite having just been approved as Bimzelx in Europe.